Frazier Financial Advisors LLC Reduces Stock Holdings in Abbott Laboratories $ABT

Frazier Financial Advisors LLC lowered its holdings in shares of Abbott Laboratories (NYSE:ABT) by 1.1% during the second quarter, Holdings Channel reports. The institutional investor owned 29,069 shares of the healthcare product maker’s stock after selling 318 shares during the quarter. Abbott Laboratories comprises about 2.8% of Frazier Financial Advisors LLC’s investment portfolio, making the stock its 8th biggest position. Frazier Financial Advisors LLC’s holdings in Abbott Laboratories were worth $3,954,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the business. Hughes Financial Services LLC acquired a new stake in shares of Abbott Laboratories in the 1st quarter valued at $27,000. Abound Financial LLC acquired a new stake in shares of Abbott Laboratories in the 1st quarter valued at $28,000. Elequin Capital LP bought a new position in shares of Abbott Laboratories in the first quarter valued at about $30,000. JCIC Asset Management Inc. bought a new position in shares of Abbott Laboratories in the first quarter valued at about $32,000. Finally, Vision Financial Markets LLC bought a new position in shares of Abbott Laboratories in the first quarter valued at about $33,000. Institutional investors and hedge funds own 75.18% of the company’s stock.

Abbott Laboratories Price Performance

Shares of ABT opened at $131.52 on Tuesday. Abbott Laboratories has a 52-week low of $110.86 and a 52-week high of $141.23. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.30 and a current ratio of 1.82. The stock has a 50 day simple moving average of $132.57 and a 200 day simple moving average of $131.60. The firm has a market capitalization of $228.90 billion, a PE ratio of 16.48, a P/E/G ratio of 2.51 and a beta of 0.69.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings data on Thursday, July 17th. The healthcare product maker reported $1.26 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.26. Abbott Laboratories had a return on equity of 18.32% and a net margin of 32.43%.The company had revenue of $11.14 billion for the quarter, compared to analysts’ expectations of $11.01 billion. During the same quarter in the prior year, the business posted $1.14 EPS. The business’s revenue was up 7.4% compared to the same quarter last year. Abbott Laboratories has set its FY 2025 guidance at 5.100-5.200 EPS. Q3 2025 guidance at 1.280-1.320 EPS. Sell-side analysts predict that Abbott Laboratories will post 5.14 EPS for the current fiscal year.

Abbott Laboratories Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Monday, November 17th. Stockholders of record on Wednesday, October 15th will be issued a dividend of $0.59 per share. This represents a $2.36 annualized dividend and a dividend yield of 1.8%. The ex-dividend date of this dividend is Wednesday, October 15th. Abbott Laboratories’s dividend payout ratio is 29.57%.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. Royal Bank Of Canada lifted their price target on Abbott Laboratories from $145.00 to $147.00 and gave the company an “outperform” rating in a report on Tuesday, July 15th. Benchmark assumed coverage on Abbott Laboratories in a report on Friday. They set a “buy” rating and a $145.00 price objective for the company. The Goldman Sachs Group boosted their price objective on Abbott Laboratories from $153.00 to $157.00 and gave the stock a “buy” rating in a report on Wednesday, October 1st. Raymond James Financial dropped their price objective on Abbott Laboratories from $142.00 to $141.00 and set an “outperform” rating for the company in a report on Friday, July 18th. Finally, William Blair raised Abbott Laboratories to a “strong-buy” rating in a report on Thursday, July 17th. Two research analysts have rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $146.17.

Insider Activity

In related news, CFO Philip P. Boudreau sold 5,550 shares of the firm’s stock in a transaction dated Friday, August 8th. The stock was sold at an average price of $134.55, for a total value of $746,752.50. Following the sale, the chief financial officer directly owned 51,003 shares of the company’s stock, valued at $6,862,453.65. This trade represents a 9.81% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Company insiders own 0.46% of the company’s stock.

Abbott Laboratories Profile

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière’s disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon.